Health regulator sets conditions to lift pause on Johnson & Johnson’s COVID-19 vaccine deployment.
The South African health regulator has recommended that the government lift the break on the administration of the COVID-19 vaccine from drugmaker Johnson & Johnson, given that certain conditions are met.
“These conditions include, but are not limited to, enhanced screening and monitoring of participants who are at high risk for a blood clotting disorder,” the South African Health Products Regulatory Authority (SAHPRA ).
“In addition, measures should be implemented to ensure the safe management of all participants who develop vaccine-induced thrombosis and thrombocytopenia (VITT),” the statement added.
The SAHPRA said on Wednesday it had recently reviewed data from Johnson & Johnson’s local research study on the vaccination of healthcare workers and found no significant safety concerns.
South Africa on Tuesday suspended deployment of the J&J vaccine in the “implementation study” after health agencies in the United States recommended suspending its use due to rare cases of blood clots in six people who received it received the blow in the country.
A US panel will meet again next week to discuss whether the hiatus on vaccine use should continue after delaying a vote on the issue earlier this week.